Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CORT

Corcept Therapeutics Inc

Oct 04 • 04:00PM ET

45.43

Dollar change +0.39
Percentage change 0.87	%

Healthcare • Biotechnology • USA • NASD

Held by: IJR IWM VTI VB FBT VXF VBK SPSM IWO IJT

Scroll to Statements

Index	RUT	P/E	40.30	EPS (ttm)	1.13	Insider Own	13.91%	Shs Outstand	103.41M	Perf Week	3.41%
Market Cap	4.75B	Forward P/E	24.65	EPS next Y	1.84	Insider Trans	-1.40%	Shs Float	89.95M	Perf Month	33.23%
Income	124.94M	PEG	-	EPS next Q	0.28	Inst Own	83.59%	Short Float	24.13%	Perf Quarter	53.95%
Sales	569.61M	P/S	8.33	EPS this Y	19.28%	Inst Trans	2.19%	Short Ratio	25.43	Perf Half Y	80.28%
Book/sh	5.71	P/B	7.95	EPS next Y	64.40%	ROA	20.17%	Short Interest	21.71M	Perf Year	75.41%
Cash/sh	4.53	P/C	10.03	EPS next 5Y	-	ROE	24.55%	52W Range	20.84 - 47.71	Perf YTD	39.87%
Dividend Est.	-	P/FCF	38.51	EPS past 5Y	9.67%	ROI	20.76%	52W High	-4.78%	Beta	0.47
Dividend TTM	-	Quick Ratio	5.48	Sales past 5Y	14.14%	Gross Margin	98.49%	52W Low	117.99%	ATR (14)	1.77
Dividend Ex-Date	-	Current Ratio	5.57	EPS Y/Y TTM	36.67%	Oper. Margin	22.46%	RSI (14)	69.52	Volatility	4.51% 4.44%
Employees	352	Debt/Eq	0.01	Sales Y/Y TTM	33.04%	Profit Margin	21.94%	Recom	1.00	Target Price	67.60
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	26.48%	Payout	0.00%	Rel Volume	0.82	Prev Close	45.04
Sales Surprise	5.58%	EPS Surprise	39.13%	Sales Q/Q	39.15%	Earnings	Jul 29 AMC	Avg Volume	853.48K	Price	45.43
SMA20	11.11%	SMA50	21.82%	SMA200	54.88%	Trades		Volume	699,789	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30
Aug-31-17	Initiated	Stifel	Buy	$20
Feb-02-17	Initiated	Ladenburg Thalmann	Buy	$14
Apr-21-15	Initiated	FBR Capital	Outperform	$12
Jan-13-14	Downgrade	Stifel	Buy → Hold

Show Previous Ratings

Oct-01-24 09:55AM	Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet (Zacks)
Sep-30-24 03:01PM	Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast (Benzinga) +5.35%
Sep-25-24 07:39AM	Does Corcept Therapeutics (CORT) Have a Long Runway for Growth? (Insider Monkey)
Sep-19-24 07:53AM	Corcept (CORT) Moves 6.5% Higher: Will This Strength Last? (Zacks)
Sep-10-24 08:46AM	Do Options Traders Know Something About Corcept (CORT) Stock We Don't? (Zacks)
11:30AM	Loading…
Aug-28-24 11:30AM	Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-27-24 12:00PM	Corcept (CORT) Upgraded to Buy: Here's Why (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade (Zacks)
Aug-01-24 09:15AM	Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jul-31-24 12:20PM	Can Corcept (CORT) Run Higher on Rising Earnings Estimates? (Zacks) +7.06%
12:00PM	Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High? (Zacks)
Jul-30-24 10:42AM	Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates (Zacks)
Jul-29-24 05:55PM	Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:54PM	Corcept: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-22-24 04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Jul-16-24 08:50AM	What Makes Corcept (CORT) a Good Fit for 'Trend Investing' (Zacks)
Jun-26-24 02:11PM	7 Biotech Stocks to Boost Your Portfolio to Peak Health (InvestorPlace)
11:13AM	Corcept (CORT) Shares Rise 20% in Three Months: Here's Why (Zacks)
06:00AM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-24-24 04:15PM	Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions (GlobeNewswire)
Jun-19-24 07:39AM	What Makes Corcept Therapeutics (CORT) a Good Investment Bet? (Insider Monkey)
Jun-14-24 09:50AM	Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks) -8.06%
Jun-13-24 05:35PM	Teva sues Corcept over mifepristone 'monopoly' for rare disorder (Reuters)
Jun-06-24 02:58AM	Insider Sale: Chief Development Officer William Guyer Sells 10,000 Shares of Corcept ... (GuruFocus.com)
Jun-03-24 08:00AM	Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome) (GlobeNewswire)
May-31-24 11:31AM	Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue? (Zacks)
03:12AM	Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ... (GuruFocus.com)
May-29-24 11:16AM	Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal (Zacks)
08:00AM	Loading…
May-28-24 08:00AM	Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing's Syndrome) (GlobeNewswire) +14.86%
May-16-24 03:12AM	Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing (MT Newswires)
May-13-24 04:01AM	Pipeline Moves: Phase III completion for Corcepts relaorilant (Clinical Trials Arena)
May-02-24 11:45AM	Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates (Zacks)
10:48AM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:30AM	Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating (MT Newswires)
08:01AM	Q1 2024 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:41AM	Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ... (GuruFocus.com)
May-01-24 05:50PM	Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024 (GuruFocus.com)
04:40PM	Corcept: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-24 08:00AM	Corcept Completes Enrollment in Phase 4 CATALYST Trial (GlobeNewswire)
Apr-24-24 04:05PM	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Apr-23-24 12:12PM	Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study (Zacks)
Apr-22-24 08:00AM	Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing's Syndrome (GlobeNewswire)
Apr-17-24 12:00PM	Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Apr-16-24 11:34AM	Corcept (CORT) Completes Enrollment in Phase II ALS Study (Zacks)
Apr-15-24 08:00AM	Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Apr-09-24 11:09AM	Corcept (CORT) Completes Enrollment in Ovarian Cancer Study (Zacks) +5.08%
Apr-08-24 08:00AM	Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Apr-01-24 08:00AM	Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome (GlobeNewswire)
Mar-25-24 10:20AM	Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry? (Zacks)
Feb-16-24 01:33PM	Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow (Zacks) -7.15%
09:04AM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:57AM	Q4 2023 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-15-24 04:47PM	Corcept: Q4 Earnings Snapshot (Associated Press Finance)
04:44PM	Corcept Therapeutics Inc Reports Significant Revenue Growth and Net Income Increase in Q4 and ... (GuruFocus.com)
04:07PM	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update (GlobeNewswire)
04:02PM	Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial (GlobeNewswire)
Feb-14-24 02:41AM	Jim Simons Bolsters Position in Corcept Therapeutics Inc (GuruFocus.com)
Feb-08-24 04:05PM	Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Jan-29-24 12:10PM	Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:00AM	Corcept Appoints Roberto Vieira as President, Oncology (GlobeNewswire)
Jan-09-24 10:48AM	Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024 (Zacks) -8.59%
Jan-08-24 08:00AM	Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program (GlobeNewswire) +13.10%
Jan-04-24 09:04AM	Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jan-02-24 02:29PM	Corcept Therapeutics Stock Is Down 27%. Its an Ideal Buying Opportunity. (Barrons.com) -25.62%
12:13PM	Corcept Therapeutics, PNM Resources fall; Johnson & Johnson rise, Tuesday, 1/2/2024 (Associated Press Finance)
11:27AM	Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva (Zacks)
08:00AM	Court Finds Corcept Therapeutics' Patents Not Infringed (GlobeNewswire)
Dec-29-23 06:43PM	Corcept loses patent spat against Teva, shares tumble (Reuters)
06:34PM	UPDATE 2-Corcept loses patent spat against Teva, shares tumble (Reuters)
06:14PM	US judge rules in favor of Teva over patent spat with Corcept (Reuters)
Dec-24-23 09:01AM	Corcept Therapeutics Inc's Chief Development Officer Sells Shares (GuruFocus.com)
Dec-08-23 09:50AM	Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock (Zacks)
Dec-06-23 11:05PM	Insider Sell: Joseph Lyon of Corcept Therapeutics Inc (CORT) Sells 5,000 Shares (GuruFocus.com)
Dec-01-23 11:31AM	Why Is Corcept (CORT) Up 0.7% Since Last Earnings Report? (Zacks)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace)
Nov-04-23 07:03AM	Insider Sell: Chief Accounting Officer Joseph Lyon Sells 5,000 Shares of Corcept Therapeutics Inc (GuruFocus.com)
Nov-02-23 02:39PM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.97%
11:23AM	Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View (Zacks)
Nov-01-23 06:18PM	Corcept Therapeutics Inc (CORT) Reports 22% Revenue Increase in Q3 2023 (GuruFocus.com)
04:42PM	Corcept: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Corcept Appoints Monica Tellado as President, Emerging Markets (GlobeNewswire)
Oct-31-23 08:40AM	Why Earnings Season Could Be Great for Corcept Therapeutics (CORT) (Zacks)
Oct-26-23 04:05PM	Corcept Initiates MONARCH A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
10:02AM	Corcept Therapeutics (CORT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-23 04:05PM	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Oct-16-23 09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
09:26AM	The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics (Zacks)
Oct-12-23 11:29AM	Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study (Zacks)
10:42AM	Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals (Zacks)
Oct-10-23 10:24AM	Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro (Zacks)
07:44AM	Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study (Zacks)
Oct-04-23 09:32AM	Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce (Zacks)
Oct-03-23 10:08AM	Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why (Zacks)
Sep-29-23 08:00AM	MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains? (Zacks) -17.41%
Sep-28-23 10:48AM	Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent (Zacks)
Sep-26-23 09:36AM	Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs (Zacks)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guyer William	Chief Development Officer	Oct 01 '24	Option Exercise	21.65	10,000	216,500	15,796	Oct 03 04:27 PM
Guyer William	Chief Development Officer	Oct 01 '24	Sale	46.28	10,000	462,800	5,796	Oct 03 04:27 PM
Robb Gary Charles	Chief Business Officer	Oct 01 '24	Option Exercise	3.29	11,000	36,190	33,772	Oct 01 07:55 PM
Robb Gary Charles	Chief Business Officer	Oct 01 '24	Sale	46.28	11,000	509,080	22,772	Oct 01 07:55 PM
Robb Gary Charles	Officer	Oct 01 '24	Proposed Sale	46.28	11,000	509,080		Oct 01 12:55 PM
Guyer William	Officer	Oct 01 '24	Proposed Sale	46.28	10,000	462,800		Oct 01 12:44 PM
Guyer William	Chief Development Officer	Sep 03 '24	Option Exercise	21.65	10,000	216,500	16,039	Sep 05 08:04 PM
Guyer William	Chief Development Officer	Sep 03 '24	Sale	35.30	10,000	353,000	6,039	Sep 05 08:04 PM
Guyer William	Officer	Sep 03 '24	Proposed Sale	35.30	10,000	353,000		Sep 03 11:33 AM
Robb Gary Charles	Chief Business Officer	Aug 26 '24	Sale	35.71	3,101	110,737	23,190	Aug 28 05:59 PM
Robb Gary Charles	Officer	Aug 26 '24	Proposed Sale	35.71	3,101	110,737		Aug 26 03:37 PM
Swisher Daniel N JR	Director	Aug 01 '24	Option Exercise	5.86	150	879	150	Aug 05 07:10 PM
Swisher Daniel N JR	Director	Aug 01 '24	Sale	38.50	150	5,775	0	Aug 05 07:10 PM
Guyer William	Chief Development Officer	Aug 01 '24	Option Exercise	21.65	10,000	216,500	16,039	Aug 05 06:56 PM
Guyer William	Chief Development Officer	Aug 01 '24	Sale	38.67	10,000	386,700	6,039	Aug 05 06:56 PM
Hunt Hazel	Chief Scientific Officer	Aug 01 '24	Option Exercise	2.81	60,000	168,600	153,354	Aug 05 06:31 PM
BELANOFF JOSEPH K	Chief Executive Officer	Jul 31 '24	Option Exercise	3.29	450,000	1,480,500	798,811	Aug 02 04:42 PM
Swisher Daniel N JR	Director	Aug 01 '24	Proposed Sale	38.50	150	5,775		Aug 01 01:36 PM
Guyer William	Officer	Aug 01 '24	Proposed Sale	38.67	10,000	386,700		Aug 01 11:26 AM
Lyon Joseph Douglas	See Remarks	Jul 01 '24	Option Exercise	11.35	5,000	56,750	14,290	Jul 03 05:16 PM
Lyon Joseph Douglas	See Remarks	Jul 01 '24	Sale	32.49	5,000	162,452	9,290	Jul 03 05:16 PM
Guyer William	Chief Development Officer	Jul 01 '24	Option Exercise	21.65	10,000	216,500	16,039	Jul 03 05:13 PM
Guyer William	Chief Development Officer	Jul 01 '24	Sale	32.49	10,000	324,900	6,039	Jul 03 05:13 PM
Robb Gary Charles	Chief Business Officer	Jul 01 '24	Option Exercise	3.29	11,000	36,190	37,291	Jul 03 04:54 PM
Robb Gary Charles	Chief Business Officer	Jul 01 '24	Sale	32.49	11,000	357,390	26,291	Jul 03 04:54 PM
Swisher Daniel N JR	Director	Jul 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Jul 03 04:54 PM
Swisher Daniel N JR	Director	Jul 01 '24	Sale	32.81	2,200	72,182	0	Jul 03 04:54 PM
Robb Gary Charles	Chief Business Officer	Jun 04 '24	Option Exercise	3.29	14,000	46,060	37,115	Jun 06 06:21 PM
Lyon Joseph Douglas	See Remarks	Jun 03 '24	Option Exercise	11.35	5,000	56,750	12,314	Jun 05 09:15 PM
Lyon Joseph Douglas	See Remarks	Jun 03 '24	Sale	30.18	5,000	150,916	7,314	Jun 05 09:15 PM
Swisher Daniel N JR	Director	Jun 03 '24	Option Exercise	5.86	2,200	12,892	2,200	Jun 05 09:15 PM
Swisher Daniel N JR	Director	Jun 03 '24	Sale	30.21	2,200	66,462	0	Jun 05 09:15 PM
Guyer William	Chief Development Officer	Jun 03 '24	Option Exercise	19.26	10,000	192,600	16,039	Jun 05 09:11 PM
Guyer William	Chief Development Officer	Jun 03 '24	Sale	32.00	10,000	320,000	6,039	Jun 05 09:11 PM
Robb Gary Charles	Chief Business Officer	May 28 '24	Option Exercise	3.29	11,000	36,190	31,203	May 30 09:00 PM
Robb Gary Charles	Chief Business Officer	May 28 '24	Sale	30.39	11,000	334,294	20,203	May 30 09:00 PM
Guyer William	Chief Development Officer	May 28 '24	Option Exercise	19.26	30,000	577,800	36,039	May 30 08:03 PM
Guyer William	Chief Development Officer	May 28 '24	Sale	32.00	30,000	960,000	6,039	May 30 08:03 PM
Maduck Sean	See Remarks	May 13 '24	Option Exercise	3.88	50,000	194,000	135,222	May 15 08:32 PM
Maduck Sean	See Remarks	May 13 '24	Sale	28.00	50,000	1,400,000	85,222	May 15 08:32 PM
Lyon Joseph Douglas	See Remarks	May 09 '24	Option Exercise	11.35	7,227	82,026	14,541	May 13 09:32 PM
Lyon Joseph Douglas	See Remarks	May 09 '24	Sale	26.00	7,227	187,902	7,314	May 13 09:32 PM
Lyon Joseph Douglas	See Remarks	May 02 '24	Option Exercise	11.35	10,830	122,920	18,144	May 06 08:23 PM
Lyon Joseph Douglas	See Remarks	May 02 '24	Sale	26.00	10,830	281,580	7,314	May 06 08:23 PM
Swisher Daniel N JR	Director	May 01 '24	Option Exercise	5.86	2,200	12,892	2,200	May 03 04:05 PM
Swisher Daniel N JR	Director	May 01 '24	Sale	23.09	2,200	50,798	0	May 03 04:05 PM
MAHONEY DAVID L	Director	Apr 10 '24	Option Exercise	1.74	30,000	52,200	30,000	Apr 12 07:00 PM
Lyon Joseph Douglas	See Remarks	Apr 04 '24	Option Exercise	11.35	5,443	61,778	12,757	Apr 08 06:16 PM
Lyon Joseph Douglas	See Remarks	Apr 04 '24	Sale	26.00	5,443	141,524	7,314	Apr 08 06:16 PM
Lyon Joseph Douglas	See Remarks	Apr 01 '24	Option Exercise	11.35	500	5,675	7,814	Apr 03 08:00 PM
Lyon Joseph Douglas	See Remarks	Apr 01 '24	Sale	26.01	500	13,004	7,314	Apr 03 08:00 PM
Swisher Daniel N JR	Director	Apr 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Apr 03 07:38 PM
Swisher Daniel N JR	Director	Apr 01 '24	Sale	25.30	2,200	55,660	0	Apr 03 07:38 PM
Maduck Sean	See Remarks	Mar 27 '24	Option Exercise	3.88	25,953	100,698	111,175	Mar 29 02:12 PM
Maduck Sean	See Remarks	Mar 27 '24	Sale	25.01	25,953	649,025	85,222	Mar 29 02:12 PM
Maduck Sean	See Remarks	Mar 18 '24	Option Exercise	3.88	17,219	66,810	92,441	Mar 20 05:09 PM
Maduck Sean	See Remarks	Mar 19 '24	Option Exercise	2.61	10,000	26,100	85,222	Mar 20 05:09 PM
Maduck Sean	See Remarks	Mar 18 '24	Sale	25.00	17,219	430,475	75,222	Mar 20 05:09 PM
Swisher Daniel N JR	Director	Mar 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Mar 05 09:02 PM
Swisher Daniel N JR	Director	Mar 01 '24	Sale	23.59	2,200	51,898	0	Mar 05 09:02 PM
Lyon Joseph Douglas	Chief Accounting Officer	Feb 16 '24	Option Exercise	11.35	1,000	11,350	7,774	Feb 21 09:11 PM
Lyon Joseph Douglas	Chief Accounting Officer	Feb 16 '24	Sale	26.00	1,000	26,000	6,774	Feb 21 09:11 PM
Maduck Sean	See Remarks	Feb 16 '24	Option Exercise	3.61	27,068	97,810	101,523	Feb 20 08:06 PM
Maduck Sean	See Remarks	Feb 15 '24	Option Exercise	3.29	4,760	15,660	79,215	Feb 20 08:06 PM
Maduck Sean	See Remarks	Feb 16 '24	Sale	25.97	27,068	702,905	74,455	Feb 20 08:06 PM
Maduck Sean	See Remarks	Feb 15 '24	Sale	25.00	4,760	119,000	74,455	Feb 20 08:06 PM
Swisher Daniel N JR	Director	Feb 01 '24	Option Exercise	5.86	2,200	12,892	2,200	Feb 02 05:39 PM
Swisher Daniel N JR	Director	Feb 01 '24	Sale	22.00	2,200	48,400	0	Feb 02 05:39 PM
Hunt Hazel	Chief Scientific Officer	Jan 08 '24	Option Exercise	3.02	50,000	151,000	123,146	Jan 12 08:06 PM
Swisher Daniel N JR	Director	Jan 02 '24	Option Exercise	5.86	2,200	12,892	2,200	Jan 04 07:14 PM
Swisher Daniel N JR	Director	Jan 02 '24	Sale	22.11	2,200	48,642	0	Jan 04 07:14 PM
Guyer William	Chief Development Officer	Dec 22 '23	Option Exercise	19.26	10,000	192,600	16,643	Dec 22 07:29 PM
Guyer William	Chief Development Officer	Dec 22 '23	Sale	32.00	10,000	320,000	6,643	Dec 22 07:29 PM
Robb Gary Charles	Chief Business Officer	Dec 04 '23	Option Exercise	3.29	15,000	49,350	37,771	Dec 06 08:56 PM
Robb Gary Charles	Chief Business Officer	Dec 06 '23	Sale	27.01	6,212	167,786	21,390	Dec 06 08:56 PM
Robb Gary Charles	Chief Business Officer	Dec 05 '23	Sale	26.27	1,381	36,277	27,602	Dec 06 08:56 PM
Swisher Daniel N JR	Director	Dec 01 '23	Option Exercise	5.86	2,200	12,892	2,200	Dec 05 07:00 PM
Swisher Daniel N JR	Director	Dec 01 '23	Sale	25.47	2,200	56,034	0	Dec 05 07:00 PM
Lyon Joseph Douglas	Chief Accounting Officer	Dec 01 '23	Option Exercise	11.35	2,568	29,147	8,422	Dec 05 06:59 PM
Lyon Joseph Douglas	Chief Accounting Officer	Dec 04 '23	Option Exercise	11.35	2,432	27,603	8,286	Dec 05 06:59 PM
Lyon Joseph Douglas	Chief Accounting Officer	Dec 01 '23	Sale	26.00	2,568	66,768	5,854	Dec 05 06:59 PM
Lyon Joseph Douglas	Chief Accounting Officer	Dec 04 '23	Sale	26.00	2,432	63,232	5,854	Dec 05 06:59 PM
Maduck Sean	See Remarks	Dec 01 '23	Option Exercise	3.02	25,000	75,444	98,291	Dec 05 06:58 PM
Maduck Sean	See Remarks	Dec 01 '23	Sale	25.56	25,000	639,048	73,291	Dec 05 06:58 PM
Lyon Joseph Douglas	Chief Accounting Officer	Nov 02 '23	Option Exercise	11.35	3,977	45,139	9,831	Nov 03 06:49 PM
Lyon Joseph Douglas	Chief Accounting Officer	Nov 01 '23	Option Exercise	11.35	1,023	11,611	6,877	Nov 03 06:49 PM
Lyon Joseph Douglas	Chief Accounting Officer	Nov 02 '23	Sale	28.11	3,977	111,794	5,854	Nov 03 06:49 PM
Lyon Joseph Douglas	Chief Accounting Officer	Nov 01 '23	Sale	28.08	1,023	28,726	5,854	Nov 03 06:49 PM
Maduck Sean	See Remarks	Nov 02 '23	Option Exercise	2.61	19,888	51,908	93,179	Nov 03 06:32 PM
Maduck Sean	See Remarks	Nov 01 '23	Option Exercise	2.61	5,112	13,342	78,403	Nov 03 06:32 PM
Maduck Sean	See Remarks	Nov 02 '23	Sale	28.11	19,888	559,056	73,291	Nov 03 06:32 PM
Maduck Sean	See Remarks	Nov 01 '23	Sale	28.08	5,112	143,545	73,291	Nov 03 06:32 PM
Swisher Daniel N JR	Director	Nov 01 '23	Option Exercise	5.86	2,200	12,892	2,200	Nov 03 06:14 PM
Swisher Daniel N JR	Director	Nov 01 '23	Sale	27.96	2,200	61,512	0	Nov 03 06:14 PM
Maduck Sean	See Remarks	Oct 10 '23	Option Exercise	2.80	18,471	51,682	92,081	Oct 12 08:19 PM
Maduck Sean	See Remarks	Oct 10 '23	Sale	27.29	18,471	504,038	73,291	Oct 12 08:19 PM
Maduck Sean	See Remarks	Oct 06 '23	Option Exercise	3.02	3,498	10,564	77,108	Oct 10 05:36 PM
Maduck Sean	See Remarks	Oct 06 '23	Sale	27.24	3,498	95,286	73,610	Oct 10 05:36 PM
Lyon Joseph Douglas	Chief Accounting Officer	Oct 06 '23	Option Exercise	11.35	2,582	29,306	8,436	Oct 10 05:26 PM
Lyon Joseph Douglas	Chief Accounting Officer	Oct 06 '23	Sale	27.24	2,582	70,334	5,854	Oct 10 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT

Corcept Therapeutics Inc

Upgrade your FINVIZ experience